We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

C4 Therapeutics Inc (CCCC) USD0.0001

Sell:$12.75 Buy:$12.77 Change: $1.07 (9.15%)
Market closed |  Prices as at close on 5 August 2022 | Switch to live prices |
Change: $1.07 (9.15%)
Market closed |  Prices as at close on 5 August 2022 | Switch to live prices |
Change: $1.07 (9.15%)
Market closed |  Prices as at close on 5 August 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

C4 Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on harnessing the body’s natural regulation of protein levels to develop therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. The Company provides technology platform, Target ORiented ProtEin Degrader Optimizer (TORPEDO), to synthesize a new class of small molecule protein degraders that are designed to destroy disease-causing proteins, including targets previously considered to be undruggable. The Company’s lead product candidates, CFT7455, is an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma (MM), peripheral T-cell lymphoma (PTCL), and mantle cell lymphoma (MCL). The Company is also developing CFT8634, an orally bioavailable degrader of a protein target called bromodomain containing 9 (BRD9), for synovial sarcoma and SMARCB1-deleted solid tumors.

Contact details

490 Arsenal Way, Suite 200
United States
+1 (617) 2310700

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$533.84 million
Shares in issue:
48.63 million
United States
US dollar

Key personnel

  • Marc Cohen
    Executive Chairman of the Board, Co-Founder
  • Andrew Hirsch
    President, Chief Executive Officer, Director
  • Lauren White
    Chief Financial Officer, Treasurer
  • Kelly Schick
    Chief People Officer
  • Stewart Fisher
    Chief Scientific Officer
  • Scott Boyle
    Chief Business Officer
  • Adam Crystal
    Chief Medical Officer
  • Jolie Siegel
    Chief Legal Officer, Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.